Finally, we evaluated the predictive value of the three uPA system components for patients with an organ-confined tumour who are usually expected to have a favourable outcome but still can progress after tumour nephrectomy given the highly aggressive nature of ccRCC. The gene discussed is PLAU; the disease is nonpapillary renal cell carcinoma.